Aldesleukin is a recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma. Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.
- Mechanism
- Curator reviewed
Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.
- Primary indication
- For treatment of adults with metastatic renal cell carcinoma.Curator reviewed · 2 structured indications
- Formula / weight
- C690H1115N177O202S6 · 15314.8 Da
- First approval
- Canada, 2025 · United States, 1992
- Also known as
- 125-L-Serine-2-133-interleukin 2 · 125-L-serine-2-133-interleukin 2 (human reduced) · Interleukin-2 aldesleukin
- Code names
- ILT-101 · r-serHuIL-2
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Aldesleukin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account